ES2153033T3 - Inhibicion de la 5-lipooxigenasa. - Google Patents

Inhibicion de la 5-lipooxigenasa.

Info

Publication number
ES2153033T3
ES2153033T3 ES95918121T ES95918121T ES2153033T3 ES 2153033 T3 ES2153033 T3 ES 2153033T3 ES 95918121 T ES95918121 T ES 95918121T ES 95918121 T ES95918121 T ES 95918121T ES 2153033 T3 ES2153033 T3 ES 2153033T3
Authority
ES
Spain
Prior art keywords
sup
sub
rent
halo
hydroxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95918121T
Other languages
English (en)
Inventor
Rodney W Stevens
Takashi Mano
Kazunari Nakao
Yoshiyuki Okumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2153033T3 publication Critical patent/ES2153033T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

NUEVOS COMPUESTOS QUE TIENEN LA CAPACIDAD DE INHIBIR UNA ENZIMA DE 5-LIPOXIGENASA Y QUE TIENEN LA FORMULA (I) Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE AR{SUP,1} ES UNA ESTRUCTURA HETEROCICLICA QUE SE SELECCIONA DE IMIDAZOLILO, PIRROLILO, PIRAZOLILO, 1,2,3-TRIAZOLILO, 1,2,4-TRIAZOLILO, INDOLILO, INDAZOLILO Y BENCIMIDAZOLILO, LA CUAL ESTA UNIDA A X{SUP,1} A TRAVES DE UN ATOMO DE NITROGENO DE ANILLO, Y LA CUAL PUEDE SER OPCIONALMENTE SUSTITUIDA CON UNO O DOS SUSTITUYENTES SELECCIONADOS DE HALO, HIDROXIDO, CIANO, AMINO, ALQUILO C{SUB,14} Y SIMILARES; X{SUP,1} ES UNA UNION DIRECTA O ALQUILENO C{SUB,1-4}; AR{SUP,2} ES FENILENO OPCIONALMENTE SUSTITUIDO CON HALO, HIDROXIDO, CIANO, AMINO Y SIMILARES; X{SUP,2} ES -A-X- O X-A- EN DONDE A ES UNA UNION DIRECTA O ALQUILENO C{SUB,1-4} Y X ES OXI, TIO, SULFINILO O SULFONILO; AR{SUP,3} ES FENILENO, PIRIDILENO, TIENILENO, FURILENO, OXAZOLILENO O TIAZOLILENO OPCIONALMENTE SUSTITUIDOS CON UNO O DOS SUSTITUYENTES SELECCIONADOS DE HALO, HIDROXIDO, CIANO, AMINO, ALQUILO C{SUB,14} Y SIMILARES; R{SUP,1} Y R{SUP,2} SON CADA UNO ALQUILO C{SUB,14}, O JUNTOS FORMAN UN GRUPO DE FORMULA -D{SUP,1}-Z-D{SUP,2}- QUE JUNTO CON EL ATOMO DE CARBONO AL QUE ESTA INCORPORADO DEFINE UN ANILLO QUE TIENE DE 3 A 8 ATOMOS, EN DONDE D{SUP,1} Y D{SUP,2} SON ALQUILENO C{SUB,1-4} Y Z ES UNA UNION DIRECTA U OXI, TIO, SULFINILO, SULFONILO O VINILENO, Y D{SUP,1} Y D{SUP,2} PUEDEN SER SUSTITUIDOS POR ALQUILO C{SUB,1-3}; E Y ES CONR{SUP,3}R{SUP,4}, CN, C(()R{SUP,3}())=N-OR{SUP,4}, COOR{SUP,3}, COR{SUP,3} O CSNR{SUP,3}R{SUP,4}, EN DONDE R{SUP,3} Y R{SUP,4} SON CADA UNO H O ALQUILO C{SUB,1-4}. ESTOS COMPUESTOS SON UTILES EN EL TRATAMIENTO O MEJORA DE ENFERMEDADES INFLAMATORIAS, ALERGIA Y ENFERMEDADES CARDIOVASCULARES EN MAMIFEROS Y COMO EL INGREDIENTE ACTIVO EN COMPOSICIONES FARMACEUTICAS PARA TRATAMIENTO DE DICHAS CONDICIONES.
ES95918121T 1994-10-18 1995-05-29 Inhibicion de la 5-lipooxigenasa. Expired - Lifetime ES2153033T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9401747 1994-10-18

Publications (1)

Publication Number Publication Date
ES2153033T3 true ES2153033T3 (es) 2001-02-16

Family

ID=14098722

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95918121T Expired - Lifetime ES2153033T3 (es) 1994-10-18 1995-05-29 Inhibicion de la 5-lipooxigenasa.

Country Status (31)

Country Link
EP (1) EP0787127B1 (es)
JP (1) JP3032579B2 (es)
CN (1) CN1093536C (es)
AT (1) ATE198474T1 (es)
AU (1) AU681520B2 (es)
BG (1) BG61768B1 (es)
CA (1) CA2202057C (es)
CO (1) CO4480026A1 (es)
CZ (1) CZ287350B6 (es)
DE (1) DE69519804T2 (es)
DK (1) DK0787127T3 (es)
ES (1) ES2153033T3 (es)
FI (1) FI971632A0 (es)
GR (1) GR3035471T3 (es)
HU (1) HU221543B (es)
IL (1) IL115581A (es)
LV (1) LV11468B (es)
MY (1) MY114680A (es)
NO (1) NO314629B1 (es)
NZ (1) NZ285163A (es)
PE (1) PE49196A1 (es)
PL (1) PL180104B1 (es)
RU (1) RU2136666C1 (es)
SI (1) SI9500392A (es)
SK (1) SK281577B6 (es)
TR (1) TR199501274A2 (es)
TW (1) TW411339B (es)
UA (1) UA45312C2 (es)
WO (1) WO1996011911A1 (es)
YU (1) YU65995A (es)
ZA (1) ZA958748B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239285B1 (en) 1998-02-06 2001-05-29 Pfizer Inc Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
US6194585B1 (en) * 1998-12-22 2001-02-27 Pfizer Inc. Process for preparing 5-lipoxygenase inhibitors
US6344563B1 (en) * 1999-08-31 2002-02-05 Timothy Norris Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
US6346624B1 (en) * 1999-08-31 2002-02-12 Pfizer Inc Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
SG87145A1 (en) * 1999-08-31 2002-03-19 Pfizer Prod Inc Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
NZ520875A (en) * 2000-03-24 2005-04-29 Euro Celtique S Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
CA2444735C (en) * 2001-04-20 2012-10-23 Novozymes A/S Lipoxygenase
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
MX2009005526A (es) * 2006-11-27 2009-06-05 Pfizer Prod Inc Analogos de pirazol.
KR20100072090A (ko) 2007-11-26 2010-06-29 화이자 인코포레이티드 5-ｌｏ 억제제로서의 피라졸 유도체
NZ631569A (en) * 2012-02-28 2016-10-28 Piramal Entpr Ltd Phenyl alkanoic acid derivatives as gpr agonists
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2001730A6 (es) * 1987-01-14 1988-06-01 Ferrer Int Procedimiento de obtencion del acio 2,3-dihidro-5-(b-(1h-imidazol-1-il) etoxi)-1h-inden-1-carboxilico
EP0462830B1 (en) * 1990-06-21 1995-10-18 Zeneca Limited Cyclic ether derivatives
IE913866A1 (en) * 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
EP0505122A1 (en) * 1991-03-21 1992-09-23 Zeneca Limited Alpha, alpha-dialkylbenzyl derivatives
EP0540165A1 (en) * 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
PL175987B1 (pl) * 1993-06-14 1999-03-31 Pfizer Nowe imidazolowe inhibitory lipoksygenazy

Also Published As

Publication number Publication date
DK0787127T3 (da) 2001-02-05
CA2202057A1 (en) 1996-04-25
EP0787127A1 (en) 1997-08-06
JPH11507322A (ja) 1999-06-29
PL180104B1 (pl) 2000-12-29
CO4480026A1 (es) 1997-07-09
NO971773L (no) 1997-06-17
BG100070A (bg) 1996-05-31
IL115581A0 (en) 1996-01-19
TR199501274A2 (tr) 1996-06-21
SK281577B6 (sk) 2001-05-10
GR3035471T3 (en) 2001-05-31
FI971632A7 (fi) 1997-04-17
HU221543B (hu) 2002-11-28
DE69519804T2 (de) 2001-04-19
NZ285163A (en) 1998-08-26
CZ287350B6 (en) 2000-10-11
FI971632A0 (fi) 1997-04-17
MY114680A (en) 2002-12-31
LV11468A (lv) 1996-08-20
EP0787127B1 (en) 2001-01-03
SK128795A3 (en) 1996-07-03
UA45312C2 (uk) 2002-04-15
WO1996011911A1 (en) 1996-04-25
NO314629B1 (no) 2003-04-22
YU65995A (sh) 1999-06-15
JP3032579B2 (ja) 2000-04-17
AU2417495A (en) 1996-05-06
CN1093536C (zh) 2002-10-30
CA2202057C (en) 2001-10-09
CN1169722A (zh) 1998-01-07
RU2136666C1 (ru) 1999-09-10
BG61768B1 (bg) 1998-05-29
CZ117797A3 (cs) 1998-06-17
TW411339B (en) 2000-11-11
LV11468B (en) 1996-12-20
ZA958748B (en) 1997-04-17
ATE198474T1 (de) 2001-01-15
HUT77363A (hu) 1998-03-30
NO971773D0 (no) 1997-04-17
AU681520B2 (en) 1997-08-28
SI9500392A (en) 1996-08-31
IL115581A (en) 1999-10-28
PL319727A1 (en) 1997-08-18
PE49196A1 (es) 1996-11-21
DE69519804D1 (de) 2001-02-08

Similar Documents

Publication Publication Date Title
ES2153033T3 (es) Inhibicion de la 5-lipooxigenasa.
ES2185999T3 (es) Derivados de quinazolina y composiciones farmaceuticas que los contienen.
BR0112160A (pt) Agentes antiinflamatórios seletivos para glicocorticóides
ATE309999T1 (de) Blutplättchen-adp-rezeptor-inhibitoren
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
ATE217321T1 (de) Aromatische heterocyclische derivate als enzyminhibitoren
UY27457A1 (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
GR3036887T3 (en) Meta-substituted phenylene sulphonamide derivatives
BG106439A (en) Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative
KR940001900A (ko) 환상 유착 억제제
ES2195121T3 (es) Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento.
ES2158314T3 (es) Oximas, hidrazonas y olefinas sustituidas como antagonistas de la neuroquinina.
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
AR016433A1 (es) Procedimiento para el tratamiento de la impotencia y composiciones.
PT981330E (pt) Composicoes topicas
EA200100994A1 (ru) 1-АМИНОТРИАЗОЛО[4,3-а]ХИНАЗОЛИН-5-ОНЫ И/ИЛИ -5-ТИОНЫ, ИНГИБИРУЮЩИЕ ФОСФОДИЭСТЕРАЗУ-IV
ES2095942T3 (es) Derivados de bencenoacetamida inhibidores del vih.
DE60014404D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
AR024918A1 (es) Derivados de ciclobuteno, su preparacion y sus usos terapeuticos.
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
DE60014394D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
ES2136291T3 (es) Derivados de pirimidina.
CO4290299A1 (es) Derivados de 1,5-benzodiazepina

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19991001

FG2A Definitive protection

Ref document number: 787127

Country of ref document: ES